Skip to main content
See every side of every news story
Published • loading... • Updated

Erectile Dysfunction Drug Shows Mixed Results in Alzheimer's

The trial met its primary endpoint in the monotherapy group, with AR1001 slowing decline by 31% and showing generally tolerable safety.

  • On Monday, South Korean biotechnology firm AriBio announced that its oral treatment AR1001 slowed clinical decline by 31% in a Phase 3 trial of patients taking no other dementia medications.
  • As a phosphodiesterase-5 inhibitor similar to Viagra, the investigational AR1001 targets underlying causes of Alzheimer's disease by relaxing blood vessels to increase blood flow to the brain.
  • Clinical results showed AR1001 was generally well-tolerated, with diarrhea and dizziness occurring at rates comparable to placebo, while biomarker analyses confirmed increased cyclic guanosine monophosphate levels.
  • Offering a simpler alternative to current infusions or injections, the therapy prompted AriBio to schedule upcoming discussions with the U.S. Food and Drug Administration regarding Phase 3 findings.
  • Enrolled in an ongoing 52-week open-label extension phase expected to conclude in 2027, participants will provide data to inform next development stages while experts stress early diagnosis remains vital for treatment success.
Insights by Ground AI

32 Articles

Lean Right

A new once-daily pill that has been dubbed “Viagra for the brain” appears to be able to significantly slow the progression of Alzheimer’s disease. According to the results of a large phase 3 clinical trial, the AR1001 treatment delayed cognitive and functional decline in patients by 31% over a year, offering the equivalent of about 3.5 additional months without the same decline.

Right

One Of World’s Most Famous Drugs Could Unlock Solution For Alzheimer’s

An erectile dysfunction drug from South Korea could become the first pill approved in the United States to slow Alzheimer’s disease.Researchers announced this week that a lower-dose version of the drug — sold as Mvix in South Korea for erectile dysfunction — helped slow mental decline in a yearlong trial of more than 1,500 people with early-stage Alzheimer’s, The Washington Post reported. But the experimental treatment, called AR1001, appeared to work only in those who were not taking other medications for dementia.Among the roughly 40% of participants who weren’t taking other dementia drugs, the pill slowed decline by about 31% compared with the placebo group. The rest of the participants, those who were on other dementia medications, exhibited little to no benefit. Across the full trial population, the benefit was not statistically significant. Researchers measured decline through assessments that included interviews with the patients and their caregivers about memory, judgment, and their daily lives.AriBio, the South Korean company repurposing the drug, said it plans to discuss with the Food and Drug Administration whether the trial results are sufficient or whether another trial is needed.If the low-dose version of Mvix were to get approved, it would be the first pill authorized in the country to slow Alzheimer’s, according to Sharon Sha, a neurologist who directs the Stanford Center for Memory Disorders and led the trial.Sha presented the group’s findings at the Clinical Trials on Alzheimer’s Disease conference on Monday.“To have a disease-modifying drug with relatively minimal side effects that is oral would be huge,” she said. “It’s very exciting and promising.”Reported side effects included diarrhea, dizziness, falls and fainting.AriBio has been testing the Viagra-like drug since late 2022 at a daily dose of 30 milligrams — less than a third of the 100-milligram dose used for erectile dysfunction.Richard Oakley, an associate director for research and innovation at Alzheimer’s Society in the United Kingdom, said the results could change the future of Alzheimer’s treatment.“These topline results are an exciting sign that we could have a totally new treatment for early Alzheimer’s disease that tackles its causes, not just its symptoms,” he said. “[The drug] takes a novel approach, relaxing blood vessels to increase blood flow to the brain. And unlike other disease-modifying treatments that have shown benefits in late-stage trials, it is taken as a once-a-day tablet, which could make treatment simpler.”

·Nashville, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 47% of the sources lean Right
47% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

NiagaraFallsReview.ca broke the news in Niagara Falls, Canada on Monday, November 16, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal